Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma
NCT ID: NCT00915096
Last Updated: 2018-08-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
121 participants
OBSERVATIONAL
2007-09-18
2013-02-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)
NCT00754117
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma
NCT02928861
Optimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism Lymphoma
NCT06795113
Combining Intratumoral Metabolic Heterogeneity and Dissemination Feature (Dmax) on 18F-FDG PET/CT Improves Prognosis Prediction in DLBCL
NCT05113576
Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT
NCT04464590
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High Tumor Burden Follicular Lymphoma
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who have not previously been treated for this disease,
* Introducing one of the criteria for high tumor burden,
* Patients aged over 18 and under 80 years,
* Patients whose ECOG condition is ≤ 2,
* Patients whose haematological functions are adequate within 28 days preceding the treatment (Hemoglobin ≥8,0g/dl; Neutrophils ≥1,5e-9/L, Platelets ≥100e-9/L),
* Patient had the PET examination less than a month before the start of chemotherapy.
Exclusion Criteria
* Patients whose lymphoma is stage 3b,
* Patients with impaired central nervous system,
* Patients regularly taking corticosteroids during the 4 weeks preceding the treatment (unless the dose administered is equivalent to ≤20 mg/day prednisone).
* Patients who have undergone major surgery during the 28 days preceding the inclusion,
* Patients with low kidney and/or liver function,
* Patients with HIV + or had an infection with HBV or HCV less than 4 weeks. Patients with hepatitis B serology is positive unless the sign is related to vaccination,
* Patients whose life expectancy ≤ 6 months,
* Patients sensitive or allergic to murine products,
* Patients who participated in another clinical trial during the 30 days preceding the recording,
* Patients with other medical problems or psychological succeptibles interfere with the study,
* Patients under adult supervision.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lymphoma Study Association
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michel MEIGNAN, Prof
Role: PRINCIPAL_INVESTIGATOR
Lymphoma Study Association
Jehan DUPUIS, MD
Role: PRINCIPAL_INVESTIGATOR
Lymphoma Study Association
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU - Besançon
Besançon, , France
CHU Avicenne
Bobigny, , France
Centre Bergognié
Bordeaux, , France
Hôpital Henri Mondor
Créteil, , France
CHU de Dijon
Dijon, , France
Clinique Victor Hugo
Le Mans, , France
Centre Hospitalier - Lens
Lens, , France
CHRU Lille
Lille, , France
CHU - Limoges
Limoges, , France
Centre Paoli-Calmettes
Marseille, , France
CHU - Nantes
Nantes, , France
Hôpital Necker
Paris, , France
Hôpital Pitié-Salpêtrière
Paris, , France
Hôpital Saint-Louis
Paris, , France
CHU Lyon Sud
Pierre-Bénite, , France
CHU Robert Debré
Reims, , France
Centre Henri Becquerel
Rouen, , France
CHU Purpan
Toulouse, , France
Hôpital Bretonneau
Tours, , France
CHU Brabois
Vandœuvre-lès-Nancy, , France
Institut Gustave Roussy
Villejuif, , France
Ospedale Cuneo
Cuneo, , Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H, Mounier N, Gallamini A, Feugier P, Soubeyran P, Colombat P, Laurent G, Berenger N, Casasnovas RO, Vera P, Paone G, Xerri L, Salles G, Haioun C, Meignan M. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. J Clin Oncol. 2012 Dec 10;30(35):4317-22. doi: 10.1200/JCO.2012.43.0934. Epub 2012 Oct 29.
Related Links
Access external resources that provide additional context or updates about the study.
GELA
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PET-FOL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.